HLB showed strength during trading on the 18th, recovering the 50,000-won level. The U.S. Federal Reserve's (Fed) decision to freeze its benchmark interest rate, combined with growing expectations for U.S. Food and Drug Administration (FDA) approval of a new liver cancer drug, are interpreted to have boosted investor sentiment.

As of 9:21 a.m. on the 18th, HLB was trading at 51,800 won, up 1,000 won (1.97%) from the previous trading day. During the session, it rose as high as 52,900 won, widening its gains. Trading volume reached approximately 390,000 shares, indicating continued investor interest. The previous day, the stock had also recovered to the 50,000-won range on an upward trend.

Market attention is focused on the FDA schedule. As the FDA review decision date (PDUFA Date) for HLB's combination therapy of liver cancer treatments rivoceranib and camrelizumab approaches in July, both expectations and caution are emerging simultaneously. Recently, FDA-related issues have been acting as a key variable for the stock price.

The macroeconomic environment also influenced investor sentiment. On the 17th (local time), the U.S. Fed maintained its benchmark interest rate at the current level during the Federal Open Market Committee (FOMC) meeting. It maintained a cautious stance on the future monetary policy path, while the market is simultaneously weighing the possibility of additional tightening and the timing of rate cuts.

On this day, the domestic stock market digested the news of the U.S. rate freeze, showing a differentiated trend across individual stocks. In particular, the biotech sector saw inflows of buying centered on stocks with new drug development momentum.

Securities firms analyzed that HLB's stock price may exhibit high volatility in the short term, depending on the progress of the FDA review and additional disclosures. As the time for the approval outcome to become visible approaches, related news flows are expected to directly impact investor sentiment.

[※ This article was written with AI assistance. Investment decisions are the responsibility of the investor, and the content included in this article may change depending on market conditions.]